Sheba 2.0 has just delivered a proof of concept for an anticancer drug synergy with a surprising lack of cardiotoxicity - in a drug combination with known cardiotoxicity.
I think now is the time to license/partner AML given the limited upside in AML, relative to other indications. The RC220 patent will (eventually) be lodged and the patent clock will start ticking over. We want FTO and CP clinical data in as many indications as possible to achieve maximum upside. I don't want the company spending the next 5 years pushing a program through on a shoestring. And it would certainly alleviate retail holder concerns regarding CR's!
Zan's opportunity as a cardioprotective anthracycline synergiser is larger than the entire AML drug market (and these numbers omit the FTO opportunity entirely). Despite this, there's still real money to be made in AML and more broadly in liquid tumours. WEHI was the research institution that discovered Venetoclax and they received US$325m for a portion of the future Venetoclax royalties (Borje's preclinical work has identified Zan synergises with Venetoclax). At the time, Venetoclax had only been approved in one indication - chronic lymphocytic leukaemia. With these results, RAC now has the opportunity to license/partner AML and fund the next few years of FTO/CP trials.
AML Market Data - https://www.globaldata.com/store/report/acute-myeloid-leukemia-market-opportunity-analysis/
ZAN Market Data - https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02654253-68RP3JPOMUJ87ILM3FFD1L8EIM/pdf?access_token=0007lzOtESbq5zc53dJAoOuzHelP
Venetoclax + Imbruvica Market Data - https://news.abbvie.com/news/press-releases/abbvie-reports-full-year-and-fourth-quarter-2022-financial-results.htm
Venetoclax Deal - https://www.wehi.edu.au/news/anti-cancer-treatment-yields-us325m-landmark-australian-deal/
Imbruvica Deal - https://www.targetedonc.com/view/abbvie-to-acquire-pharmacyclics-ibrutinib-for-21-billion
Sheba 2.0 has just delivered a proof of concept for an...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.005(0.34%) |
Mkt cap ! $242.5M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.50 | $1.43 | $62.91K | 43.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5700 | $1.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 591 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.46 |
Change
-0.005 ( 0.23 %) |
||||
| Open | High | Low | Volume | ||
| $1.44 | $1.49 | $1.43 | 9034 | ||
| Last updated 13.08pm 24/05/2024 ? | |||||
| RAC (ASX) Chart |